ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …
Posted: February 14, 2012 at 1:50 am
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Monday (Feb. 6) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and retina division chief at UCLA’s Jules Stein Eye Institute. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.
“With the treatment of this third Stargardt’s patient at Jules Stein Eye Institute, we have now completed the treatment of the first cohort of patients under our clinical protocol for phase I/II of our U.S. SMD trial,” said Gary Rabin, chairman and chief executive officer of ACT. “We will continue to regularly monitor the three SMD patients in this trial, and by early spring anticipate review of their progress and safety-related data by the Data and Safety Monitoring Board (DSMB). With approval of the DSMB, we would then advance to the next cohort of patients and administer a higher dosage of RPE cells. In the context of all three trials we have running, this patient is the fifth person worldwide to be treated with our hESC-derived RPE cells. To date, there have been no complications or side effects due to the RPE cells, and we remain cautiously optimistic that our ongoing clinical programs will demonstrate the safety and tolerability of ACT’s stem cell-derived RPE cells.”
Each of the three clinical trials being undertaken by the company in the U.S. and Europe will enroll 12 patients, with cohorts of three patients each in an ascending dosage format. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with SMD or dry age-related macular degeneration (dry AMD) at 12 months, the study’s primary endpoint. Preliminary results relating to both early safety and biological function for the first two patients in the United States, one SMD patient and one dry AMD patient, were recently reported in The Lancet. On January 20, 2012, the first SMD patient to be enrolled in the Company’s U.K. clinical trial was treated at Moorfields Eye Hospital in London.
Further information about patient eligibility for the SMD study and the concurrent study on dry AMD is also available on www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.
About Stargardt's Disease
Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
Originally posted here:
ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ...
- Eli and Edythe Broad Center of Regeneration Medicine and ... - October 30th, 2015
- Molecular & Cellular Medicine - October 29th, 2015
- Sickle cell anemia Treatments and drugs - Mayo Clinic - October 29th, 2015
- How are stem cells used in medicine today? - HowStuffWorks - October 29th, 2015
- Oxidative Medicine and Cellular Longevity An Open Access ... - October 29th, 2015
- Department of Regenerative Medicine and Cell Biology - October 29th, 2015
- Sickle Cell Anemia: MedlinePlus - National Library of Medicine - October 29th, 2015
- Personalized RegenerativeMedicine : Dr David Steenblock - October 29th, 2015
- Cell Therapy and Regenerative Medicine - October 29th, 2015
- The Power of Stem Cells | California's Stem Cell Agency - October 29th, 2015
- Herbal medicine | Cancer Research UK - October 29th, 2015
- UR Stem Cell and Regenerative Medicine Institute (SCRMI) - October 29th, 2015
- Penn Medicine News: Genetically Modified "Serial Killer" T ... - October 29th, 2015
- Beta cell regeneration - Center for Regenerative Medicine ... - October 29th, 2015
- The Stem Cell Theory of Cancer - Stanford Medicine Center - October 29th, 2015
- What is a cell? - Genetics Home Reference - October 16th, 2015
- Cell Therapy & Regenerative Medicine - University of Utah ... - October 13th, 2015
- Sickle Cell Anemia: Learn About SCD Symptoms and Treatment - September 26th, 2015
- Research - Stem Cell Biology and Regenerative Medicine ... - September 26th, 2015
- Sickle Cell Disease (Sickle Cell Anemia ... - MedicineNet - September 26th, 2015
- T Cell Therapy (CTL019) | The Children's Hospital of ... - September 15th, 2015
- Knoepfler Lab Stem Cell Blog | Building innovative ... - September 10th, 2015
- Cell culture - Wikipedia, the free encyclopedia - September 6th, 2015
- What are the potential uses of human stem cells and the ... - August 17th, 2015
- One type of airway cell can regenerate another lung cell type - April 13th, 2015
- Limber Lungs: One Type of Airway Cell Can Regenerate Another Lung Cell Type - April 13th, 2015
- Regenestem Network Announces Plans to Attend the 23rd Annual World Congress on Anti-Aging Medicine May 7-9, 2015 - April 6th, 2015
- 'Open' stem cell chromosomes reveal new possibilities for diabetes - April 3rd, 2015
- Key mechanism identified in tumor-cell proliferation in pediatric bone cancers - April 3rd, 2015
- UCI team gets $5 million to create stem cell treatment for Huntington's disease - March 28th, 2015
- Sungduan: Growth factors - March 28th, 2015
- Cleveland Clinic Researchers First to Demonstrate Significant Blocking of Opioid Tolerance With Mesenchymal Stem Cell ... - March 25th, 2015
- Johns Hopkins Medicine, based in Baltimore, Maryland - March 23rd, 2015
- stem cell medicine Jakarta tangerang serpong bsd bintaro - Video - March 21st, 2015
- Global Stem Cells Group to Hold Practical Adipose-Derived Stem Cell Harvesting, Isolation and Re-integration Training ... - March 20th, 2015
- Boston Stem Cell Biotech Start-up Asymmetrex Will Present Essential Technologies for Stem Cell Medical Engineering at ... - March 18th, 2015
- A Single-Cell Breakthrough: newly developed technology dissects properties of single stem cells - March 18th, 2015
- BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York - March 18th, 2015
- Global Stem Cells Group to Participate in the 25th Argentine Congress of Aesthetic Medicine in Buenos Aires April 9-10 ... - March 17th, 2015
- Boosting A Natural Protection Against Alzheimer's Disease - March 13th, 2015
- Media portray unrealistic timelines for stem cell therapies - March 12th, 2015
- Stem cells lurking in tumors can resist treatment - March 12th, 2015
- Building custom blood cells to battle sickle cell disease - March 11th, 2015
- Johns Hopkins researchers engineer custom blood cells - March 10th, 2015
- Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the ... - March 10th, 2015
- Mast cell - Wikipedia, the free encyclopedia - March 9th, 2015
- Achieving gender equality in science, engineering and medicine - March 9th, 2015
- Seven strategies to advance women in science - March 9th, 2015
- British biotech firm sets crowdfunding record with heart drug - March 9th, 2015
- A good night's sleep keeps your stem cells young - March 9th, 2015
- Howe's recovery shows stem-cell advances - March 1st, 2015
- Translational Regenerative Medicine: Market Prospects 2015-2025 - February 28th, 2015
- Stem cellrecruiting hydrogels based on self-assembling peptides for tissue regeneration - February 25th, 2015
- Sertoli cell - Wikipedia, the free encyclopedia - February 17th, 2015
- Global Stem Cells Group Announces Alliance with Regenerative Technology - February 11th, 2015
- Biotech firm Cell Therapy claims crowdfunding record with heart drug - February 10th, 2015
- Two UC San Diego Scientists Receive Stem Cell Technology Grants - February 3rd, 2015
- Regenestem Network and Gilberto Hernandez Falcon, M.D. Open Stem Cell Clinic in Yucatan - January 31st, 2015
- Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ... - January 29th, 2015
- Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ... - January 29th, 2015
- Gordie Howe's stem cell therapy raises concerns among medical experts - January 29th, 2015
- Gordie Howe's stem cell therapy raises concerns among experts - January 29th, 2015
- BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer ... - January 27th, 2015
- Keeping the Kraken asleep - January 27th, 2015
- Helmholtz International Fellow Award for Prof. Amanda Fisher from London - January 27th, 2015
- Regenestem Network, a division of Global Stem Cells Group, Announces Launch of New Stem Cells and Regenerative ... - January 22nd, 2015
- Scientists announce revolutionary culturing technique for liver and pancreas - January 22nd, 2015
- New Type of Cell Found to Repair Lung Injury in Mice - January 18th, 2015
- Stem cells derived from amniotic tissues have immunosuppressive properties - January 16th, 2015
- Global Stem Cells Group to Move Headquarters to Larger Miami Lakes Office Complex - January 14th, 2015
- Peter S. Kim Named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford - January 13th, 2015
- Renowned professor's book addresses stem cell biology & regenerative medicine - January 13th, 2015
- Circadian rhythms regulate skin stem cell metabolism and expansion, study finds - January 7th, 2015
- Cord Blood Banking Leader, Cryo-Cell International, Continues to Support the Advancement of Regenerative Medicine - January 6th, 2015
- Scientists Develop Pioneering Method to Define Stages of Stem Cell Reprogramming - January 6th, 2015
- Pioneering method developed to define stages of stem cell reprogramming - January 6th, 2015
- The Irvine Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Orange County, California - January 5th, 2015
- Ten years in, California's stem cell program is getting a reboot - January 4th, 2015
- Two-thirds of cancer cases are "bad luck," study says - January 1st, 2015
- 'Bad Luck' of Random Mutations Plays Predominant Role in Cancer, Study Shows - January 1st, 2015